Last reviewed · How we verify
Hemay022
At a glance
| Generic name | Hemay022 |
|---|---|
| Sponsor | Tianjin Hemay Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer (PHASE3)
- Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer (PHASE1)
- Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer (PHASE1)
- A Food-Effect Study of Hemay022 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hemay022 CI brief — competitive landscape report
- Hemay022 updates RSS · CI watch RSS
- Tianjin Hemay Pharmaceutical Co., Ltd portfolio CI